SYDNEY, April 15 (Reuters) - Shares of China's Duality Biotherapeutics 9606.HK were set to rise 91.3% in their Hong Kong debut on Tuesday after the company raised $213 million in an initial public offering launched as financial markets reacted savagely to the U.S tariffs package.
(Reporting by Scott Murdoch in Sydney and Donny Kwok in Hong Kong; Editing by Tom Hogue)
((Scott.Murdoch@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。